146 related articles for article (PubMed ID: 16732158)
1. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine.
Fletcher M; Leeming J; Cartwright K; Finn A;
Pediatr Infect Dis J; 2006 Jun; 25(6):559-60. PubMed ID: 16732158
[TBL] [Abstract][Full Text] [Related]
2. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
[TBL] [Abstract][Full Text] [Related]
3. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.
Li ST; Tancredi DJ
Pediatrics; 2010 Jan; 125(1):26-33. PubMed ID: 19948570
[TBL] [Abstract][Full Text] [Related]
4. Etiology and Incidence of Pleural Empyema in South African Children.
Zampoli M; Kappos A; Wolter N; von Gottberg A; Verwey C; Mamathuba R; Zar HJ
Pediatr Infect Dis J; 2015 Dec; 34(12):1305-10. PubMed ID: 26267310
[TBL] [Abstract][Full Text] [Related]
5. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine.
Hendrickson DJ; Blumberg DA; Joad JP; Jhawar S; McDonald RJ
Pediatr Infect Dis J; 2008 Nov; 27(11):1030-2. PubMed ID: 18845981
[TBL] [Abstract][Full Text] [Related]
6. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal empyema: impact of immunization.
Jhaveri R
Pediatr Infect Dis J; 2006 Sep; 25(9):854; author reply 854. PubMed ID: 16940853
[No Abstract] [Full Text] [Related]
8. Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation.
Madhi F; Levy C; Morin L; Minodier P; Dubos F; Zenkhri F; Dommergues MA; Mezgueldi E; Levieux K; ; Béchet S; Varon E; Cohen R;
J Pediatric Infect Dis Soc; 2019 Nov; 8(5):474-477. PubMed ID: 30407519
[TBL] [Abstract][Full Text] [Related]
9. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
10. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Mokaddas E; Albert MJ
Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
[TBL] [Abstract][Full Text] [Related]
11. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
13. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.
Hanquet G; Lernout T; Vergison A; Verhaegen J; Kissling E; Tuerlinckx D; Malfroot A; Swennen B; Sabbe M;
Vaccine; 2011 Apr; 29(16):2856-64. PubMed ID: 21342667
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
15. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.
von Kries R; Siedler A; Schmitt HJ; Reinert RR
Clin Infect Dis; 2000 Aug; 31(2):482-7. PubMed ID: 10987709
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
Shibl AM; Memish ZA; Al-Kattan KM
Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
18. A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice.
Fraser D; Givon-Lavi N; Bilenko N; Dagan R
Clin Infect Dis; 2001 Aug; 33(4):421-7. PubMed ID: 11462175
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults.
Scott D; Ruckle J; Dar M; Baker S; Kondoh H; Lockhart S
Pediatr Int; 2008 Jun; 50(3):295-9. PubMed ID: 18533940
[TBL] [Abstract][Full Text] [Related]
20. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
